低剂量阿司匹林是全膝关节置换术后所有患者风险分层中最安全的静脉血栓栓塞预防措施
该研究利用2012至2022年全国数据库分析126,692例全膝关节置换术患者,低剂量阿司匹林使用比例从7.65%升至55.29%。在倾向匹配队列中,低剂量阿司匹林组较其他预防方案组在高风险和低风险患者中均降低深静脉血栓、肺栓塞、出血、感染和再住院的几率。
要点
- 全膝关节置换术后低剂量阿司匹林使用比例从2012年7.65%升至2022年55.29%。
- 低剂量阿司匹林在高风险和低风险患者中均降低深静脉血栓、肺栓塞、出血、感染和再住院几率。
- 低风险患者较高风险患者更可能接受低剂量阿司匹林(OR 1.17;95% CI 1.15-1.20)。
核心结论
- 在大规模全膝关节置换术患者中,低剂量阿司匹林是跨各种风险分层的安全有效预防方法,支持2022年ICM-VTE声明。
研究设计与样本
- 利用全国数据库的倾向匹配队列研究,纳入2012至2022年间60个医疗机构的126,692例全膝关节置换术患者。
- 根据ICM-VTE确定的合并症划分静脉血栓栓塞风险分层,比较低剂量阿司匹林(81 mg)与其他预防方案。
主要发现
- 低剂量阿司匹林使用比例从2012年7.65%增至2022年55.29%,其他预防方案从96.25%降至42.98%。
- 低风险患者较高风险患者更可能接受低剂量阿司匹林(OR 1.17;95% CI 1.15-1.20)。
- 低剂量阿司匹林组低风险和高风险患者较其他预防方案组均降低深静脉血栓、肺栓塞、出血、感染和再住院的几率。
关键数值与推荐
- 低剂量阿司匹林仅用队列低风险患者较高风险患者接受阿司匹林的OR为1.17(95% CI 1.15-1.20)。
- 低剂量阿司匹林剂量为81 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The International Consensus Meeting on Venous Thromboembolism (ICM-VTE) in 2022 proclaimed low-dose aspirin as the most effective agent in patients across all risk profiles undergoing joint arthroplasty. However, data on large patient populations assessing trends in chemoprophylactic choices and related outcomes following total knee arthroplasty (TKA) remain scant. The present study was designed to characterize the clinical use of various chemoprophylactic agents in patients undergoing TKA and to determine the efficacy of aspirin compared with other agents in patient groups stratified by VTE risk profiles. METHODS: This study utilized a national database to determine the proportion of patients undergoing TKA who received low-dose aspirin versus other chemoprophylaxis between 2012 and 2022. VTE risk profiles were determined on the basis of comorbidities established in the ICM-VTE. The odds ratios (ORs) and 95% confidence intervals (CIs) between various classes of thromboprophylaxis in patients with high and low risk of VTE were calculated. The odds of deep-vein thrombosis (DVT), pulmonary embolus (PE), bleeding events, infections, mortality, and hospitalizations were also assessed in the 90-day postoperative period for propensity-matched cohorts receiving low-dose (81 mg) aspirin only versus other prophylaxis, segregating patients by VTE risk profile. RESULTS: A total of 126,692 patients undergoing TKA across 60 health-care organizations were included. The proportion of patients receiving low-dose aspirin increased from 7.65% to 55.29% between 2012 and 2022, whereas the proportion of patients receiving other chemoprophylaxis decreased from 96.25% to 42.98%. Low-dose-aspirin-only use increased to approximately 50% in both high-risk and low-risk populations but was more likely in low-risk populations (OR, 1.17; 95% CI, 1.15 to 1.20) relative to high-risk populations. Both low-risk and high-risk patients in the low-dose-aspirin-only cohorts had decreased odds of DVT, PE, bleeding, infections, and hospitalizations compared with other prophylaxis regimens. CONCLUSIONS: The findings of the present study on a very large population of patients undergoing TKA support the recent ICM-VTE statement by showing that low-dose aspirin is a safe and effective method of prophylaxis in patients across various risk profiles. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Lavu MS, Porto JR, Hecht CJ, et al. Low-Dose Aspirin Is the Safest Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty Across All Patient Risk Profiles. J Bone Joint Surg Am. 2024. PMID: 38753809. doi:10.2106/JBJS.23.01158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。